The Impact of CFS/ME on Employment and Productivity in the UK: a Cross-sectional Study Based on the CFS/ME National Outcomes Database
Overview
Affiliations
Background: Few studies have investigated factors associated with discontinuation of employment in patients with CFS/ME or quantified its impact on productivity.
Methods: We used patient-level data from five NHS CFS/ME services during the period 01/04/2006-31/03/2010 collated in the UK CFS/ME National Outcomes Database. We used logistic regression to identify factors associated with discontinuation of employment. We estimated UK-wide productivity costs using patient-level data on duration of illness before assessment by a CFS/ME service, duration of unemployment, age, sex and numbers of patients, in conjunction with Office for National Statistics income and population data.
Results: Data were available for 2,170 patients, of whom 1,669 (76.9%) were women. Current employment status was recorded for 1,991 patients (91.8%), of whom 811 patients (40.7%) were currently employed and 998 (50.1%) had discontinued their employment "because of fatigue-related symptoms". Older age, male sex, disability, fatigue, pain, and duration of illness were associated with cessation of employment. In a multivariable model, age, male sex, and disability remained as independent predictors. Total productivity costs among the 2,170 patients due to discontinuation of employment in the years preceding assessment by a specialist CFS/ME service (median duration of illness=36 months) were £49.2 million. Our sample was equivalent to 4,424 UK adults accessing specialist services each year, representing productivity costs to the UK economy of £102.2 million. Sensitivity analyses suggested a range between £75.5-£128.9 million.
Conclusions: CFS/ME incurs huge productivity costs amongst the small fraction of adults with CFS/ME who access specialist services.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection.
Unger E, Lin J, Wisk L, Yu H, LHommedieu M, Lavretsky H JAMA Netw Open. 2024; 7(7):e2423555.
PMID: 39046739 PMC: 11270135. DOI: 10.1001/jamanetworkopen.2024.23555.
Determining the societal value of a prospective drug for ME/CFS in Germany.
Gandjour A PLoS One. 2024; 19(7):e0307086.
PMID: 39024303 PMC: 11257356. DOI: 10.1371/journal.pone.0307086.
Hasan A, Khan N, Munna N, Choton W, Arefin M, Khan M Brain Behav. 2024; 14(6):e3553.
PMID: 38873875 PMC: 11177034. DOI: 10.1002/brb3.3553.
Impact of Long COVID on productivity and informal caregiving.
Kwon J, Milne R, Rayner C, Lawrence R, Mullard J, Mir G Eur J Health Econ. 2023; 25(7):1095-1115.
PMID: 38146040 PMC: 11377524. DOI: 10.1007/s10198-023-01653-z.
Orji N, Cox I, Jason L, Chen G, Zhao T, Rogerson M Qual Life Res. 2023; 33(1):45-57.
PMID: 37561337 PMC: 10784392. DOI: 10.1007/s11136-023-03498-8.